ScholarGate
Βοηθός

Σύγκριση μεθόδων

Εξετάστε τις επιλεγμένες μεθόδους δίπλα-δίπλα· οι γραμμές που διαφέρουν επισημαίνονται.

Μελέτη Φάσης IV με Ζεύγη×Αντιστοίχιση Βαθμολογίας Προδιάθεσης×
ΠεδίοΕπιδημιολογίαΕρευνητική Στατιστική
ΟικογένειαProcess / pipelineProcess / pipeline
Έτος προέλευσης1980s–1990s (formalized in post-marketing regulatory frameworks)1983
ΔημιουργόςRegulatory tradition (FDA, EMA); matching methodology from Rosenbaum & Rubin (1983)Paul Rosenbaum and Donald Rubin
ΤύποςObservational study designMethod
Θεμελιώδης πηγήStrom, B. L., & Kimmel, S. E. (Eds.). (2005). Textbook of Pharmacoepidemiology. Wiley. ISBN: 978-0470029244Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55. DOI ↗
Εναλλακτικές ονομασίεςmatched post-marketing surveillance study, Phase IV matched cohort study, matched pharmacoepidemiological study, post-authorization matched safety studyPSM, propensity score weighting, covariate balance
Συναφείς53
ΣύνοψηA Matched Phase IV study is a post-marketing observational design in which patients who received an approved drug (or intervention) are matched to comparable non-exposed patients — or patients on an alternative therapy — to evaluate real-world safety, effectiveness, or long-term outcomes. Conducted after regulatory approval, it combines the epidemiological rigour of matching with the breadth of post-authorization pharmacovigilance, generating evidence that randomized trials are rarely powered or timed to provide.Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias.
ScholarGateΣύνολο δεδομένων
  1. v1
  2. 2 Πηγές
  3. PUBLISHED
  1. v1
  2. 3 Πηγές
  3. PUBLISHED

Μετάβαση στην αναζήτηση Λήψη διαφανειών

ScholarGateΣύγκριση μεθόδων: Matched Phase IV Study · Propensity Score Matching. Ανακτήθηκε στις 2026-06-18 από https://scholargate.app/el/compare